Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Accumulated Expenses (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Other Accumulated Expenses for 11 consecutive years, with $549000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 54.29% to $549000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $549000.0 through Dec 2025, down 54.29% year-over-year, with the annual reading at $549000.0 for FY2025, 54.29% down from the prior year.
  • Other Accumulated Expenses hit $549000.0 in Q4 2025 for Voyager Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $7.0 million in Q3 2024 to a low of $549000.0 in Q4 2025.
  • Historically, Other Accumulated Expenses has averaged $4.0 million across 5 years, with a median of $3.2 million in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: soared 6543.04% in 2021 and later crashed 62.47% in 2024.
  • Year by year, Other Accumulated Expenses stood at $5.6 million in 2021, then crashed by 49.17% to $2.8 million in 2022, then increased by 12.99% to $3.2 million in 2023, then plummeted by 62.47% to $1.2 million in 2024, then crashed by 54.29% to $549000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for VYGR at $549000.0 in Q4 2025, $1.2 million in Q4 2024, and $7.0 million in Q3 2024.